Directed evolution of adeno-associated virus (AAV) yields mutant vectors that can evade neutralizing antibodies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout

Bob Crimi
References
Ness, J.E. et al. Adv. Protein Chem. 55, 261–292 (2000).
Soong, N.W. et al. Nat. Genet. 25, 436–439 (2000).
Maheshri, N. et al. Nat. Biotech. 24, 198–204 (2006).
Gao, G. et al. Curr. Gene Ther. 5, 285–297 (2005).
Romano, G., Drug News Perspect. 18, 311–316 (2005).
Duan, D. et al. Mol. Ther. 4, 383–391 (2001).
Muzyczka, N. & Warrington, K.H. Jr. Hum. Gene Ther. 16, 408–416 (2005).
Zaiss, A.K. & Muruve, D.A. Curr. Gene Ther. 5, 323–331 (2005).
Wu, P. et al. J. Virol. 74, 8635–8647 (2000).
Lochrie, M.A. et al. J. Virol. 80, 821–834 (2005).
Moskalenko, M. et al. J. Virol. 74, 1761–1766 (2000).
Padron, E. et al. J. Virol. 79, 5047–5058 (2005).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Asokan, A., Samulski, R. AAV does the shuffle. Nat Biotechnol 24, 158–160 (2006). https://doi.org/10.1038/nbt0206-158
Issue Date:
DOI: https://doi.org/10.1038/nbt0206-158